1/16
07:02 pm
zbio
Zenas BioPharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
Low
Report
Zenas BioPharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
1/16
04:15 pm
zbio
Zenas BioPharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Zenas BioPharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
1/15
10:00 am
zbio
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zenas BioPharma, Inc. - ZBIO
Medium
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zenas BioPharma, Inc. - ZBIO
1/13
03:53 pm
zbio
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zenas BioPharma, Inc. - ZBIO
Low
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zenas BioPharma, Inc. - ZBIO
1/13
01:36 am
zbio
Assessing Zenas BioPharma (ZBIO) Valuation After Positive INDIGO Phase 3 Trial News [Yahoo! Finance]
High
Report
Assessing Zenas BioPharma (ZBIO) Valuation After Positive INDIGO Phase 3 Trial News [Yahoo! Finance]
1/10
01:07 am
zbio
Zenas BioPharma (NASDAQ:ZBIO) was downgraded by analysts at
Wall Street
High
Report
Zenas BioPharma (NASDAQ:ZBIO) was downgraded by analysts at
Wall Street
1/8
10:16 pm
zbio
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zenas BioPharma, Inc. - ZBIO
Low
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zenas BioPharma, Inc. - ZBIO
1/8
10:00 am
zbio
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zenas BioPharma, Inc. - ZBIO
Low
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zenas BioPharma, Inc. - ZBIO
1/7
07:12 pm
zbio
Zenas BioPharma Touts Phase 3 Win, But Stock Crashes [Yahoo! Finance]
Low
Report
Zenas BioPharma Touts Phase 3 Win, But Stock Crashes [Yahoo! Finance]
1/6
12:50 pm
zbio
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zenas BioPharma, Inc. - ZBIO
Medium
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zenas BioPharma, Inc. - ZBIO
1/6
12:41 pm
zbio
ZBIO Tanks Despite Positive Data From Rare Autoimmune Diseases Study [Yahoo! Finance]
Medium
Report
ZBIO Tanks Despite Positive Data From Rare Autoimmune Diseases Study [Yahoo! Finance]
1/6
07:17 am
zbio
Zenas BioPharma (NASDAQ:ZBIO) had its "buy" rating reaffirmed by analysts at Jefferies Financial Group Inc..
Low
Report
Zenas BioPharma (NASDAQ:ZBIO) had its "buy" rating reaffirmed by analysts at Jefferies Financial Group Inc..
1/6
05:13 am
zbio
Zenas: Maintaining 'Strong Buy' As Cross-Trial Comparison Of Obexelimab Should Not Be A Factor [Seeking Alpha]
Low
Report
Zenas: Maintaining 'Strong Buy' As Cross-Trial Comparison Of Obexelimab Should Not Be A Factor [Seeking Alpha]
1/5
04:00 pm
zbio
Zenas BioPharma (NASDAQ:ZBIO) was downgraded by analysts at Morgan Stanley from an "overweight" rating to an "equal weight" rating. They now have a $19.00 price target on the stock.
Medium
Report
Zenas BioPharma (NASDAQ:ZBIO) was downgraded by analysts at Morgan Stanley from an "overweight" rating to an "equal weight" rating. They now have a $19.00 price target on the stock.
12/30
04:16 pm
zbio
Zenas BioPharma (NASDAQ:ZBIO) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Zenas BioPharma (NASDAQ:ZBIO) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
12/23
04:14 pm
zbio
Zenas BioPharma (NASDAQ:ZBIO) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Zenas BioPharma (NASDAQ:ZBIO) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
12/22
12:23 pm
zbio
Zenas BioPharma Seen Attractive Ahead of IgG4-RD Phase 3 Update, Wedbush Says [Yahoo! Finance]
Medium
Report
Zenas BioPharma Seen Attractive Ahead of IgG4-RD Phase 3 Update, Wedbush Says [Yahoo! Finance]
12/22
08:42 am
zbio
Zenas BioPharma (NASDAQ:ZBIO) had its "outperform" rating reaffirmed by analysts at Wedbush. They now have a $45.00 price target on the stock.
High
Report
Zenas BioPharma (NASDAQ:ZBIO) had its "outperform" rating reaffirmed by analysts at Wedbush. They now have a $45.00 price target on the stock.
12/19
04:23 pm
zbio
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
High
Report
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
12/19
04:15 pm
zbio
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
High
Report
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
12/16
04:43 pm
zbio
Zenas BioPharma (NASDAQ:ZBIO) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Zenas BioPharma (NASDAQ:ZBIO) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
12/16
08:43 am
zbio
Zenas BioPharma (NASDAQ:ZBIO) had its "buy" rating reaffirmed by analysts at HC Wainwright.
High
Report
Zenas BioPharma (NASDAQ:ZBIO) had its "buy" rating reaffirmed by analysts at HC Wainwright.
12/15
08:17 am
zbio
Zenas BioPharma's Partner, InnoCare Pharma, Announces Achievement of Primary Endpoint in Phase 2b Study of Orelabrutinib, a BTK Inhibitor, for Systemic Lupus Erythematosus [Yahoo! Finance]
High
Report
Zenas BioPharma's Partner, InnoCare Pharma, Announces Achievement of Primary Endpoint in Phase 2b Study of Orelabrutinib, a BTK Inhibitor, for Systemic Lupus Erythematosus [Yahoo! Finance]
12/15
07:05 am
zbio
Zenas BioPharma’s Partner, InnoCare Pharma, Announces Achievement of Primary Endpoint in Phase 2b Study of Orelabrutinib, a BTK Inhibitor, for Systemic Lupus Erythematosus
High
Report
Zenas BioPharma’s Partner, InnoCare Pharma, Announces Achievement of Primary Endpoint in Phase 2b Study of Orelabrutinib, a BTK Inhibitor, for Systemic Lupus Erythematosus
12/15
04:23 am
zbio
Zenas Prepares For INDIGO Phase 3 Readout - Reinstating Buy Rating [Seeking Alpha]
High
Report
Zenas Prepares For INDIGO Phase 3 Readout - Reinstating Buy Rating [Seeking Alpha]